Toxoplasma gondii poses serious risks during pregnancy and to those with weakened immune systems, and Clinicians must ...
Sleep, often overlooked in routine HIV care, could be the missing vital sign that determines how long and how well people ...
The Kingdom of Buganda has reported a major milestone in its HIV/AIDS response efforts, revealing that Shs2.9 billion collected through the Kabaka's 70th Birthday Run has been successfully utilised to ...
Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to reduce the severity of infections such as bird flu, and cure chronic conditions ...
With a focus on Massachusetts, Rhode Island and Vermont, a project funded by the National Institute on Drug Abuse will analyze trends in drug use and barriers to care with the goal of strengthening ...
Former CEO of Microsoft talks about climate change and helping those countries most impacted at a talk at Caltech.
Recently incarcerated individuals with HIV face challenges in achieving sustained viral suppression (SVS) due to social conditions and health care access issues. Young and frequently incarcerated ...
In these uncertain, volatile, and unprecedented times, the role of science is more important than ever. Scientific advances that benefit humanity and ensure planetary sustainability for current and ...
HIV can throw the body clock off balance, leaving many people living with the virus in a constant state of “jet lag,” according to a new study in The Lancet HIV involving Wits University researchers.
Zacks Investment Research on MSN
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
Gilead Sciences, Inc.’s GILD posted 3% year-over-year growth in total revenues for the third quarter of 2025. Total revenues comprise product sales and royalty, contract and other revenues. While ...
Professor Derek Yellon discusses the increasing prevalence of cardiovascular diseases (CVD) in Africa and the associated ...
In the European Union (EU) Member States, QDENGA is indicated for the prevention of dengue disease in individuals from four years of age and should be administered subcutaneously as a 0.5 mL dose at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results